NRXP PE Ratio & Valuation,Is NRXP Overvalued

NRXP Relative Valuation

NRXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NRXP is overvalued; if below, it's undervalued.

Historical Valuation

NRX Pharmaceuticals Inc (NRXP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.66 is considered Undervalued compared with the five-year average of 0.68. The fair price of NRX Pharmaceuticals Inc (NRXP) is between 6.90 to 8.01 according to relative valuation methord. Compared to the current price of 2.07 USD , NRX Pharmaceuticals Inc is Undervalued By 69.98%.

Relative Value

Fair Zone

6.90-8.01

Current Price：2.07

69.98%

Undervalued

29.91

18.42

EV/EBITDA

NRX Pharmaceuticals Inc. (NRXP) has a current EV/EBITDA of 18.42. The 5-year average EV/EBITDA is 0.28. The thresholds are as follows: Strongly Undervalued below -8.26, Undervalued between -8.26 and -3.99, Fairly Valued between 4.54 and -3.99, Overvalued between 4.54 and 8.81, and Strongly Overvalued above 8.81. The current Forward EV/EBITDA of 18.42 falls within the Strongly Overvalued range.

10.53

EV/EBIT

NRX Pharmaceuticals Inc. (NRXP) has a current EV/EBIT of 10.53. The 5-year average EV/EBIT is -1.60. The thresholds are as follows: Strongly Undervalued below -21.67, Undervalued between -21.67 and -11.63, Fairly Valued between 8.43 and -11.63, Overvalued between 8.43 and 18.47, and Strongly Overvalued above 18.47. The current Forward EV/EBIT of 10.53 falls within the Overvalued range.

0.66

NRX Pharmaceuticals Inc. (NRXP) has a current PS of 0.66. The 5-year average PS is 0.16. The thresholds are as follows: Strongly Undervalued below -0.50, Undervalued between -0.50 and -0.17, Fairly Valued between 0.49 and -0.17, Overvalued between 0.49 and 0.82, and Strongly Overvalued above 0.82. The current Forward PS of 0.66 falls within the Overvalued range.

5.93

P/OCF

NRX Pharmaceuticals Inc. (NRXP) has a current P/OCF of 5.93. The 5-year average P/OCF is -2.53. The thresholds are as follows: Strongly Undervalued below -16.69, Undervalued between -16.69 and -9.61, Fairly Valued between 4.55 and -9.61, Overvalued between 4.55 and 11.63, and Strongly Overvalued above 11.63. The current Forward P/OCF of 5.93 falls within the Overvalued range.

12.44

P/FCF

NRX Pharmaceuticals Inc. (NRXP) has a current P/FCF of 12.44. The 5-year average P/FCF is -0.23. The thresholds are as follows: Strongly Undervalued below -6.66, Undervalued between -6.66 and -3.45, Fairly Valued between 2.99 and -3.45, Overvalued between 2.99 and 6.21, and Strongly Overvalued above 6.21. The current Forward P/FCF of 12.44 falls within the Strongly Overvalued range.

NRX Pharmaceuticals Inc (NRXP) has a current Price-to-Book (P/B) ratio of -2.22. Compared to its 3-year average P/B ratio of -13.85 , the current P/B ratio is approximately -83.94% higher. Relative to its 5-year average P/B ratio of 5.99, the current P/B ratio is about -137.17% higher. NRX Pharmaceuticals Inc (NRXP) has a Forward Free Cash Flow (FCF) yield of approximately -21.49%. Compared to its 3-year average FCF yield of -60.33%, the current FCF yield is approximately -64.38% lower. Relative to its 5-year average FCF yield of -54.01% , the current FCF yield is about -60.22% lower.

-2.22

P/B

Median3y

-13.85

Median5y

5.99

-21.49

FCF Yield

Median3y

-60.33

Median5y

-54.01

Competitors Valuation Multiple

The average P/S ratio for NRXP's competitors is 1340.32, providing a benchmark for relative valuation. NRX Pharmaceuticals Inc Corp (NRXP) exhibits a P/S ratio of 0.66, which is -99.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NRXP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NRXP in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NRX Pharmaceuticals Inc (NRXP) currently overvalued or undervalued?

What is NRX Pharmaceuticals Inc (NRXP) fair value?

NRXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of NRX Pharmaceuticals Inc (NRXP) is between 6.90 to 8.01 according to relative valuation methord.

How does NRXP's valuation metrics compare to the industry average?

What is the current P/B ratio for NRX Pharmaceuticals Inc (NRXP) as of Dec 15 2025?

As of Dec 15 2025, NRX Pharmaceuticals Inc (NRXP) has a P/B ratio of -2.22. This indicates that the market values NRXP at -2.22 times its book value.

What is the current FCF Yield for NRX Pharmaceuticals Inc (NRXP) as of Dec 15 2025?

As of Dec 15 2025, NRX Pharmaceuticals Inc (NRXP) has a FCF Yield of -21.49%. This means that for every dollar of NRX Pharmaceuticals Inc’s market capitalization, the company generates -21.49 cents in free cash flow.

What is the current Forward P/E ratio for NRX Pharmaceuticals Inc (NRXP) as of Dec 15 2025?

As of Dec 15 2025, NRX Pharmaceuticals Inc (NRXP) has a Forward P/E ratio of 29.91. This means the market is willing to pay $29.91 for every dollar of NRX Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for NRX Pharmaceuticals Inc (NRXP) as of Dec 15 2025?

As of Dec 15 2025, NRX Pharmaceuticals Inc (NRXP) has a Forward P/S ratio of 0.66. This means the market is valuing NRXP at $0.66 for every dollar of expected revenue over the next 12 months.

NRXP Valuation